Specific features of therapy for disordered urination in menopausal women

Balan V.E.

Moskovskiĭ oblastnoĭ NII akusherstva i ginekologii

Amirova Zh.S.

V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Moscow, Russia

Kovalev L.A.

Nauchnyĭ tsentr akusherstva, ginekologii i perinatologii imeni akademika V.I. Kulakova, Moskva;
GBOU VPO "Pervyĭ Moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet imeni I.M. Sechenova"

Krasnopol'skaia I.V.

Moskovskiĭ oblastnoĭ NII akusherstva i ginekologii

Ermakova E.I.

FGBU "Nauchnyĭ tsentr akusherstva, ginekologii i perinatologii im. akad. V.I. Kulakova" Ministerstva zdravookhraneniia Rossii, Moskva

Specific features of therapy for disordered urination in menopausal women

Authors:

Balan V.E., Amirova Zh.S., Kovalev L.A., Krasnopol'skaia I.V., Ermakova E.I.

More about the authors

Journal: Russian Bulletin of Obstetrician-Gynecologist. 2015;15(3): 29‑34

DOI: 10.17116/rosakush201515329-34

Downloaded: 44

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Balan VE, Amirova ZhS, Kovalev LA, Krasnopol'skaia IV, Ermakova EI. Specific features of therapy for disordered urination in menopausal women. Russian Bulletin of Obstetrician-Gynecologist. 2015;15(3):29‑34. (In Russ.)
https://doi.org/10.17116/rosakush201515329-34

Подписка 2025-2 (Russian Bulletin of Obstetrician-Gynecologist)

Close metadata

The paper gives a literature review reflecting the current possibilities of treatment in women with overactive bladder depending upon age. It shows the susceptibility of the lower urogenital tract to sex steroids, the significance of which in the genesis of overactive bladder is beyond question. Different hormone replacement therapy options as part of combination therapy are considered. The authors declare no conflicts of interest.

Keywords:

overactive bladder

menopause

urogenital disorders

estrogens

antimuscarinic agents

Authors:

Balan V.E.

Moskovskiĭ oblastnoĭ NII akusherstva i ginekologii

Amirova Zh.S.

V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Moscow, Russia

Kovalev L.A.

Nauchnyĭ tsentr akusherstva, ginekologii i perinatologii imeni akademika V.I. Kulakova, Moskva;
GBOU VPO "Pervyĭ Moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet imeni I.M. Sechenova"

Krasnopol'skaia I.V.

Moskovskiĭ oblastnoĭ NII akusherstva i ginekologii

Ermakova E.I.

FGBU "Nauchnyĭ tsentr akusherstva, ginekologii i perinatologii im. akad. V.I. Kulakova" Ministerstva zdravookhraneniia Rossii, Moskva

List of references:

Legendre G., Ringa V., Fauconnier A. Menopause, hormone treatment and urinary incontinence at midlife. Maturitas 2013; 74: 26—30.
Temml C., Haidinger G., Schmidbauer J., Schatzl G., Madersbacher S. Urinary incontinence in both sexes: prevalence rates and impact on quality of life and sexual life. Neurourol Urodyn 2000; 19: 3: 259—271.
Sand P.K., Goldberg R.P., Dmochowski R.R., McIlwain M., Dahl N.V. The impact of the overactive bladder syndrome on sexual function: a preliminary report from the multicenter assessment of transdermal therapy in overactive bladder with oxybutynin trial. Am J Obstet Gynecol 2006; 195: 1730—1735.
McGrother C.W., Donaldson M.M., Shaw C., Matthews R.J., Hayward T.A., Dallosso H.M., Jagger C., Clarke M., Castleden C.M. Storage symptoms of the bladder: prevalence, incidence and need for services in the UK. BJU International 2004; 93: 763—769.
Hagglund D., Walker-Engstrom M.L., Larsson G., Leppert J. Changes in urinary incontinence and quality of life after four years. A population-based study of women aged 22—50 years. Scand J Primary Health Care 2004; 22: 112—117.
Sherburn M., Guthrie J.R., Dudley E.C., O’Connell H.E., Dennerstein L. Is incontinence associated with menopause? Obstet Gynecol 2001; 98: 628—633.
Townsend M.K., Danforth K.N., Lifford K.L., Rosner B., Curhan G.C., Resnick N.M., Grodstein F. Incidence and remission of urinary incontinence in middle-aged women. Am J Obstet Gynecol 2007; 97: 1671—1675.
Moller L.A., Lose G., Jorgensen T. Incidence and remission rates of lower urinary tract symptoms at one year in women aged 40–60: longitudinal study. Br Med J 2000; 320: 1429—1432.
Waetjen L.E., Ye J., Feng W.Y., Johnson W.O., Greendale G.A., Sampselle C.M., Sternfield B., Harlow S.D., Gold E.B. Association between menopausal transition stages and developing urinary incontinence. Obstet Gynecol 2009; 114: 989—998.
Waetjen L.E., Feng W.Y., Ye J., Johnson W.O., Greendale G.A., Sampselle C.M., Sternfield B., Harlow S.D., Gold E.B. Factors associated with worsening and improving urinary incontinence across the menopausal transition. Obstet Gynecol 2008; 111: 3: 667—677.
Mishra G.D., Cardozo L., Kuh D. Menopausal transition and the risk of urinary incontinence: results from a British prospective cohort. BJU International 2010; 106: 1170—1175.
Zhu L., Lang J., Liu C., Han S., Huang J., Li X. The epidemiological study of women with urinary incontinence and risk factors for stress urinary incontinence in China. Menopause 2009; 16: 4: 831—836.
Gopal M., Sammel M.D., Arya L.A., Freeman E.W., Lin H., Gracia C. Association of change in estradiol to lower urinary tract symptoms during the menopausal transition. Obstet Gynecol 2008; 112: 5: 1045—1052.
Waetjen L.E., Johnson W.O., Xing G., Feng W.Y., Greendale G.A., Gold E.B. Serum estradiol levels are not associated with urinary incontinence in midlife women transitioning through menopause. Menopause 2011; 18: 12: 1283—1290.
Teleman P.M., Persson J., Mattiasson A., Samsioe G. The relation between urinary incontinence and steroid hormone levels in perimenopausal women. A report from the Women’s Health in the Lund Area (WHILA) study. Acta Obstet Gynecol Scand 2009; 88: 8: 927—932.
Principles of embryology according to Pettenu. Moscow: Mir 1983; 2: 168—180. (In Russ).
Gosling J.A., Dixon J. Embryology and ultrastructur of the female lower urinary tract in: Urogynecology and urodinamic Theory and Practice. Ed by Donald R. Ostergard, A.E. Bent. Baltimore 1991; 19—30.
Utian W.H., Archer D.F., Bachmann G.A., Gallagher C., Grodstein Fn., Heiman J.R., Henderson V.W., Hodis H.N., Karas R.H., Lobo R.A., Manson J.E., Reid R.L., Schmidt P.J., Stuenkel C.A. Estrogen and progestogen use in postmenopausal women: position statement of The North American Menopause Society. Menopause 2008; 15: 4: 584—603.
Balan V.E., Kovaleva L.A. Gormony i urogenital’nyi epitelii. Glava v rukovodstve dlya praktikuyushchikh vrachei «Sheika matki, vlagalishche, vulva». Hormones and urogenital epithelium. Ed by S.I. Rogovskaya, E.V. Lipova. Status praesens 2014; 741—777. (In Russ).
Cavallini E., Dinaro A., Giocolano C., Caringella A.M., Ferreri R., Tutino V., Loverro G. Estrogen receptor (ER) and ER-related receptor expressoin in normal and atrophic human vagina. Maturitas 2008; 59: 3: 219—225.
Position statement. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 2013; 20: 90: 888—902.
22. Gormley А.E., Lightner D.J., Burgio K.L., Chai T.C., Clemens J.Q., Culkin D.J., Das A.K., Foster H.E. Jr, Scarpero H.M., Tessier C.D., Vasavada S.P. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol 2012; 188: 6 Suppl: 2455—2463.
Chapple C.R., Khullar V., Gabriel Z., Muston D., Bitoun C.E., Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008; 54: 3: 543—562.
Novara G., Galfano A., Secco S., D’Elia C., Cavalleri S., Ficarra V., Artibani W. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol 2008; 54: 4: 740—763.
Al-Baghdadi O., Ewies A. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview. Climacteric 2009; 12: 2: 91—105.
Cardozo L., Lose G., McClish D., Versi E. A systematic review of the effects of estrogens for symptoms suggestive of overactive bladder. Acta Obstet Gynecol Scand 2004; 83: 10: 892—897.
Ewies A.A., Alfhaily F. Topical vaginal estrogen therapy in managing postmenopausal urinary symptoms: a reality or a gimmick? Climacteric 2010; 13: 405—418.
Serati M., Salvatore S., Uccella S., Cardozo L., Bolis P. Is there a synergistic effect of topical oestrogens when administered with antimuscarinics in the treatment of symptomatic detrusor overactivity? Eur Urol 2009; 55: 3: 713—719.
Nelken R.S., Ozel B.Z., Leegant A.R., Felix J.C., Mishell D.R. Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder. Menopause 2011; 18: 9: 962—966.
Tseng L.H., Wang A.C., Chang Y.L., Soong Y.K., Lloyd L.K., Ko Y.J. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome. Neurourol Urodyn 2009; 28: 47—51.
Legendre G., Ringa V., Fauconnier A. Menopause, hormone treatment and urinary incontinence at midlife. Maturitas 2013; 74: 26—30.
Hendrix S.L., Cochrane B.B., Nygaard I.E., Handa V.L., Barnabei V.M., Iglesia C., Aragaki A., Naughton M.J., Wallace R.B., McNeeley S.G. Effects of estrogen with and without progestin on urinary incontinence. J Am Med Assoc 2005; 293: 8: 935—948.
Steinauer J., Waetjen L.E., Vittinghoff E., Subak L.L., Hulley S.B., Grady D., Lin F., Brown J.S. Postmenopausal hormone therapy: does it cause incontinence? Obstet Gynecol 2005; 106: 5: 940—945.
Cody J.D., Richardson K., Moehrer B., Hextall A., Glazener C.M. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev 2009; 7: 4: CD001405.
Grodstein F., Lifford K., Resnick N.M. Postmenopausal hormone therapy and risk of developing urinary incontinence. Obstet Gynecol 2004; 103: 254—260.
Northington G.M., de Vries H.F., Bogner H.R. Self-reported estrogen use and newly incident urinary incontinence among postmenopausal community-dwelling women. Menopause 2012; 19: 290—295.
Liapis A., Bakas P., Georgantopoulou C., Creatsas G. The use of oestradiol therapy in postmenopausal women after TVT-O anti-incontinence surgery. Maturitas 2010; 66: 1: 101—106.
Zullo M.A., Plotti F., Calcagno M., Palaia I., Muzii L., Manci N., Angioli R., Panici P.B. Vaginal estrogen therapy and overactive bladder symptoms in postmenopausal patients after a tension-free vaginal tape procedure: a randomized clinical trial. Menopause 2005; 12: 4: 421—427.
Fritel X., Ringa V., Quiboeuf E., Fauconnier A. Female urinary incontinence, from pregnancy to menopause, a review of epidemiologic and pathophysiologic findings. Acta Obstetet Gynecol Scand 2012; 91: 8: 901—910.
Ewies A.A., Alfhaily F. Topical vaginal estrogen therapy in managing postmenopausal urinary symptoms: a reality or a gimmick? Climacteric 2010; 13: 5: 405—418.
Robinson D., Cardozo L. Estrogens and the lower urinary tract. Neurourol Urodyn 2011; 30: 5: 754—757.
Thuroff J.W., Abrams P., Andersson K.E., Artibani W., Chapple C.R., Drake M.J., Hampel C., Neisius A., Schröder A., Tubaro A. EAU guidelines on urinary incontinence. Eur Urol 2011; 59: 3: 387—400.
Fritel X., Fauconnier A., Bader G., Cosson M., Debodinance P., Deffieux X., Denys P., Dompeyre P., Faltin D., Fatton B., Haab F., Hermieux J.F., Kerdraon J., Mares P., Mellier G., Michel-Laaengh N., Nadeau C., Robain G., de Tayrac R., Jacquetin B. Diagnosis and management of adult female stress urinary incontinence: guidelines for clinical practice from the French College of Gynaecologists and Obstetricians. Eur J Obstet Gynecol Reprod Biol 2010; 151: 1: 14—19.

Close metadata